
Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news
Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size
Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury
TD Cowen, Barclays and BTIG jt bookrunners
With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data
HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%